


***Best Practices:***  
***Integration of Risk Management  
and Corrective and Preventive  
Action***

Presented by:


**Norman L. Collazo**

**Worldwide Director of Strategic Quality**

Cordis Corporation, a Johnson & Johnson company




*The views expressed are those of the speaker and are not necessarily those of Cordis Corporation or Johnson & Johnson. The views are offered to provide an overview of issues related to Risk Management and Corrective and Preventive Action activities.*




# Agenda

- ❖ About Cordis Corporation
- ❖ What is Risk Management
- ❖ What is CAPA
  - ❖ Key Definitions
- ❖ Inputs and Triggers
- ❖ Root Cause Analysis
- ❖ Preventive Actions
- ❖ Continuous Improvement: Some Suggestions
- ❖ Q&A




## *About Cordis*

- Cordis Corporation was established in Miami, Florida, in 1959 as a medical device corporation and rapidly gains recognition for being a pioneer in innovative devices and products for interventional vascular medicine and electrophysiology.
- In 1966, Cordis introduced the first full line of “Pre-shaped” Judkins catheters. These shapes become the industry standard.
- In 1990, Cordis introduced the first PTCA (percutaneous transluminal coronary angioplasty) balloon utilizing nylon balloon technology. This material becomes the industry standard.
- In 1996, Cordis Corporation merged with Johnson & Johnson Interventional Systems Co. to form Cordis Corporation, a Johnson & Johnson company with approximately 3,500 employees worldwide.



## *About Cordis - What did this mean??*

- In 2003, Cordis received FDA approval to market its CYPHER® Sirolimus-eluting Coronary Stent in the U.S., making it the first drug/device combination product for the treatment of restenosis.
  - As a combination device, what parts of CFR 210/211 apply?
    - Annual Product Review? **Yes.**
    - Stability Testing changes? **Yes.**
  - Impact of launch on:
    - Complaints System - **Major**
    - Regulatory Requirements - **Major**
    - Compliance Profile - **Major**
    - CAPA System - **Major**
    - Risk Management - **Major**




## *RISK*



Probability of occurrence +  
severity of the hazard



Physical injury or damage to health  
of people or damage to property  
or the environment




## *What is Risk Management?*

***Companies want to know the impact (Risk) of decisions being made on the product.***


### *Challenge*

- ✚ "...each stakeholder places a different value on the probability of harm occurring and on the detriment that might be suffered on exposure to a hazard."



# *Systems of Feedback*


- Design feedback
  - Customer Complaints
- Management Review
- CAPA Escalation and Risk Management
- Acceptable Risk



Proactive

Reactive






# *Risk Management*


## Challenges:

- ⊕ No clear escalation from when an input reaches a threshold and when a CAPA is opened
- ⊕ Risk assessment process/tool not established or well defined
  - ⊞ Combination products (e.g., drug/devices) have shifted landscape
  - ⊞ Adverse events due to the drug/device interaction
  - ⊞ Procedural aspects of the case e.g., new techniques or uses, incorrect technique
- ⊕ CAPA process not linked to risk management documentation (Design Controls documents, process and product FMEAs, etc.)
- ⊕ Data not readily available to establish occurrence and therefore calculate risk



# *CAPA Escalation: Health Hazard Evaluations*

- Complaint and MDRs provide inputs into health hazard evaluations (HHE) by characterizing:
  - Observed or potential harm to the patient
  - Relevant procedural issues
  - Contributing anatomical or pharmacological factors
  - Demographics of affected patients
  - Comparison of risks associated with same hazards for competitive products or alternate treatment modality
  
- Ultimately, HHEs act as a risk-benefit analysis for post-launch issues to characterize the necessity for a CAPA and the need for field action




# *Acceptable Risk*


- What is the acceptable risk problem?


A decision process (Fischhoff, et. al. 1981) that

- Specifies the objectives to measure the desirability or lack thereof
- Defines possible options, including no action
- Identifies the consequences of each option and likelihood of occurrence
- Specifying the desirability of consequences
- Analyzing the options and selecting the “most acceptable” option



# PLAN






# BALANCE




**RISK**

**BENEFIT**




## *Why Risk as part of CAPA System?*

- ✚ What is the impact of risk to the CAPA system?
- ✚ What hurdles will we encounter?



# *CAPA Escalation: Connecting Risk Management and Trending*


- Critical questions that drive into the CAPA process and determine the depth of investigation/priority of CAPA:
  - Is this a new or unknown hazard?
  - Has the severity increased? Decreased?
  - Has the frequency of occurrence increased?
  - Have the causes of the hazard been confirmed?
  - Are there new causes of the hazard that have inadequate or no mitigation?
  
- Complaint and MDR investigations and trends provide answers to many of the questions above



*Why is CAPA important?*

***88% of all FDA Warning Letters  
and 483's issued in 2003 were  
CAPA related***





# Key Definitions

## **Nonconformance (NC)**

- Any noncompliance with the requirements of the Quality System (product and non-product).

## **Correction**


- Repair, rework, or adjustment related to the disposition of an existing nonconformity. Corrections are typically one-time fixes.

## **Corrective Action (CA)**


- Action taken to eliminate the **causes** of an *existing* nonconformity, defect, or other undesirable situation in order to prevent recurrence.


## **Preventive Action (PA)**

- Action taken to eliminate the **cause** of a *potential* nonconformity, defect, or other undesirable situation in order to prevent occurrence and improve quality trends.





# What is CAPA?





# CAPA Process






After root cause, revisit the risk.




a) If  $>$ , need additional action


- Field Action
- additional CA & PA

b) If  $<$ , can re-evaluate new risk.

- then decide intolerable to Broadly Acceptable, limited by resources








# Inputs and Triggers

## Internal Sources:

- ⊕ Acceptance activities
- ⊕ Calibration and Maintenance records
- ⊕ Design Control system
- ⊕ Management Reviews/**Annual Product Reviews**
- ⊕ Nonconformances (product and **non-product**)
- ⊕ Packaging and Labeling materials
- ⊕ Quality Audits
- ⊕ Returned products
- ⊕ Risk Management documents
- ⊕ Service and Installation records
- ⊕ **Six Sigma/Process Excellence programs**
- ⊕ SPC monitoring
- ⊕ Stability studies
- ⊕ **And more...**

Remember to include ancillary improvements, project systems, etc.




# Inputs and Triggers

## External Sources:

- ⊕ Customer complaints
- ⊕ Customer feedback
- ⊕ External Quality Audit reports
- ⊕ FDA/ISO/EN/IVDD feedback
- ⊕ Product warranty
- ⊕ Recalls/field actions
- ⊕ Identification of any other condition/issue that does not comply with:
  - ▣ Your own Quality System and/or
  - ▣ ISO/EN/IVDD standards (e.g., ISO 9001, ISO 13485, EN 46001, etc.)
  - ▣ FDA regulations (e.g., 21 CFR 820, 21 CFR 210/211, 21 CFR 600, 21 CFR Part 11, etc.)
- ⊕ And more...

Remember to track & trend, use risk assessment tools




# *Inputs and Triggers*

## Challenges:

- ⊕ Inputs not clearly defined or established
- ⊕ Trigger thresholds not established
- ⊕ Focus on reactive metrics (Nonconformances, Complaints, Audit Observations)
- ⊕ Data not easily retrievable
- ⊕ Data not easy to analyze for trends






# *Root Cause Analysis*

## Challenges:


- ⊕ Poor/lack of technical skills to conduct root cause analysis
- ⊕ Poor/lack of writing skills in documenting root cause analysis
- ⊕ Poor/little business knowledge in conducting root cause analysis across processes, systems, product lines, and Quality Systems



# *Preventive Actions*

## Challenges:


- When everything is corrective, how can the organization assign resources to address Preventive Action?
- Risk assessment may not be designed to address elevation to CAPA for a potential issue or improvement (Preventive Action).
- CAPA metrics tend to focus on closure rates, cycle time, number of open CAPAs, etc. Preventive Actions are, in most cases, longer-term solutions across processes, systems, product lines, and Quality Systems and will take more time to close.



# *From Corrective to Preventive – some suggestions:*

## Inputs and Triggers


- Clearly define inputs and establish thresholds
- Implement predictive metrics/indicators
- Routinely review and act on sources of product and quality data
- **Make data reporting available and easy to users and management**



# *From Corrective to Preventive – some suggestions:*

## Risk Management


- Establish elevation mechanisms to CAPA
- Use a risk assessment process to allow prioritization of CAPAs and elevation to Management
- Use a risk assessment process that allows CAPAs for Preventive Action
- Link CAPA to Risk Management documentation (e.g., FMEAs, Design Control documents)
- Make data reporting available and easy to users and management




# *From Corrective to Preventive – some suggestions:*


## Root Cause Analysis

- Establish clear roles and responsibilities for conducting investigation
- Increase technical skills on root cause analysis tools
- Improve writing skills
- Use team approach to conduct investigation to increase business and technical knowledge
- Align with Six Sigma/Process Excellence



# CAPA Process and Six Sigma (DMAI<sup>2</sup>C)






# *From Corrective to Preventive – some suggestions:*

## Preventive Action

- Implement predictive metrics/indicators
- Routinely review and act on sources of product and quality data
- Use a risk assessment process that allows CAPAs for Preventive Action
- Improve linkage between CAPA into Design Controls
- Take a holistic view of issues
  - Can it link to other Quality Systems, product lines, systems, and/or processes?




# *From Corrective to Preventive – some suggestions:*

## CAPA Process

- ⊕ Integrate, integrate, integrate across business solutions and across sites
- ⊕ Streamline/Lean your CAPA process
- ⊕ Implement a global process for all sites
- ⊕ Establish technical and user support for your CAPA system
- ⊕ Leverage sister companies for design and experience (lessons learned)
- ⊕ Establish joint partnership between business/system owner and Information Technology for continuous improvement efforts
- ⊕ Project team (business and Information Technology) need to be experts in the process as well as the software solution
- ⊕ Take a holistic view of the CAPA process
  - ▣ Does it link to other Quality Systems and business systems?






# *From Corrective to Preventive – some suggestions:*

## Software Solution


- Integrate, integrate, integrate across software solutions and sites
- Implement a global software solution
- Establish technical and user support for your CAPA system
- Leverage sister companies for infrastructure and validation
- Ensure that the hardware is reliable and support users needs including connection time, processing speed, 24x7 availability, etc.
- Increase technical expertise and involvement from your software vendor during initial design and implementation phases
- Project team (business and Information Technology) need to be experts in the process as well as the software solution
- Take a holistic view of the CAPA process and software solution
  - Can/does it link to other Quality Systems and business systems?



# *From Corrective to Preventive – some suggestions:*

## Management Support and Oversight


- Ensure Management oversight and commitment
- Align CAPA with company, departmental, and individual goals and objectives
- Create rewards and recognition programs
- Establish joint partnership between business/system owner and Information Technology for continuous improvement efforts
- **Align metrics from departmental to corporate level**



# *Annual Product Review - Requirements*


Does it apply to devices? **Yes**, for combination devices such as, drug/device, biologics/device, etc..

- ❑ Written records subject to this review include, but are not limited to, the following:
  - ❑ Manufacturing and quality records from lots or batches of drug/device combination products manufactured within the previous year, including:
    - receiving inspection
    - in-process
    - final release testing results
    - deviations
    - investigations
    - change control records
    - quality system trends




# *Annual Product Review (continued)*

- ❑ Post market quality records such as:
  - complaints
  - Medical Device Reporting (MDR)
  - adverse events
  - field actions
  - product corrections
  - regulatory submissions
  - returned or salvaged products
  - product stability data



# *Conclusions - Annual Product Review*

- Covers the product cradle to grave. Presents management a view of product and process behavior over time.
- Is influenced by all aspects of the Quality System - including in process and release testing.
- Supports decisions related to design control, process validation and control as well as user drift.
- Identifies trends/opportunities across mfg lines or sites.



## *BIG Lesson Learned*

Process Owner (Users)

+


System (Procedures + Software)

=

Sustainability



Leads to Cultural Change



# Q&A

**Contact Info:**


Norman L. Collazo

Cordis Corporation

14201 NW 60<sup>th</sup> Avenue, Miami Lakes, FL 33014

[Ncollaz1@CRDUS.jnj.com](mailto:Ncollaz1@CRDUS.jnj.com)

786.313.2266



## *Thanks go to:*

*Miguel Avila - CAPA Director, Cordis*

*John Daley - Executive Director Quality Systems, Cordis*

*Bryan Olin - Executive Director Product Quality Services, Cordis*

*Frances Akelewicz - Practical Solutions*

*Many others over the years for their patience and guidance.....*